Umezawa Small Molecular Immunomodifiers of Microbial Origin

Fundamental and Clinical Studies of Bestatin
1. Auflage 2014
ISBN: 978-1-4831-9033-4
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 268 Seiten, Web PDF

Small Molecular Immunomodifiers of Microbial Origin: Fundamental and Clinical Studies of Bestatin focuses on the results of experimental and clinical studies suggesting that bestatin and small molecular weight immunity-enhancing agents can contribute to the treatment of cancer and resistant infections. The selection first offers information on the screening, discoveries, and genetics of microbial secondary metabolites and activity of bestatin. Topics include the effect of bestatin on colony formation of murine bone marrow progenitor cells in vitro; antitumor effect of bestatin on murine transplantable tumors; and structures and properties of bestatin, amastatin, forphenicine, and esterastin. The text then examines the effects of bestatin on DNA and RNA metabolism in T-cells and levamisole and bestatin in immunodefficient aged mice. The text examines the influence of bestatin on the lymphoid system in humans, natural killer activity, and bone marrow. The preliminary phase I study of bestatin in lung cancer cases and malignant skin tumors are discussed. Topics include dosage schedule, clinical findings, and changes in immunological parameters. The selection is a vital reference for readers interested in the applications of bestatin in the treatment of cancer and resistant infections.

Autoren/Hrsg.

Umezawa, Hamao

Inhaltsverzeichnis

1;Front Cover;1
2;Small Molecular Immunomodifiers of Microbial Origin: Fundamental and Clinical Studies of Bestatin;4
3;Copyright Page;5
4;Table of Contents;8
5;PREFACE;6
6;CHAPTER 1. SMALL MOLECULAR WEIGHT IMMUNOMODIFIERS PRODUCED BY MICROORGANISMS: THEIR SCREENING AND DISCOVERIES, AND THE GENETICS OF MICROBIAL SECONDARY METABOLITES;16
6.1;GENETICS OF MICROBIAL SECONDARY METABOLITES;17
6.2;A BIOCHEMICAL SCREENING METHOD FOR SMALL MOLECULAR WEIGHT IMMUNOMODIFIERS;19
6.3;STRUCTURES AND PROPERTIES OF BESTATIN, AMASTATIN, FORPHENICINE, AND ESTERASTIN;21
6.4;CONCLUSION WITH FUTURE PROSPECT;28
6.5;SUMMARY;29
6.6;REFERENCES;29
7;CHAPTER 2. ACTIVITY OF BESTATIN: ENHANCEMENT OF IMMUNE RESPONSES AND ANTITUMOR EFFECT;32
7.1;EFFECT OF BESTATIN ON IMMUNE RESPONSES;33
7.2;MITOGENICITY OF BESTATIN ON MURINE SPLENIC LYMPHOCYTES;36
7.3;ANTITUMOR EFFECT OF BESTATIN ON MURINE TRANSPLANTABLE TUMORS;40
7.4;THE EFFECT OF BESTATIN ON COLONY FORMATION OF MURINE BONE MARROW PROGENITOR CELLS IN VITRO;47
7.5;DISCUSSION AND CONCLUSION;49
7.6;SUMMARY;51
7.7;REFERENCES;52
8;CHAPTER 3. EFFECT OF BESTATIN ON DNA AND RNA METABOLISM IN T-CELLS;54
8.1;STUDIES IN THE ANIMAL SYSTEM;56
8.2;STUDIES WITH CELLS IN CULTURE;65
8.3;REMARKS;69
8.4;SUMMARY;70
8.5;REFERENCES;71
9;CHAPTER 4. LEVAMISOLE AND BESTATIN IN IMMUNODEFFICIENT AGED MICE;74
9.1;MATERIALS AND METHODS;75
9.2;RESULTS;77
9.3;DISCUSSION;81
9.4;SUMMARY;82
9.5;REFERENCES;83
10;CHAPTER 5. THE INFLUENCE OF BESTATIN ON THE LYMPHOID SYSTEM IN THE HUMAN;86
10.1;MATERIALS AND METHODS;87
10.2;RESULTS;90
10.3;DISCUSSION;107
10.4;SUMMARY;111
11;CHAPTER 6. EFFECT OF BESTATIN ON NATURAL KILLER ACTIVITY;116
11.1;MATERIALS AND METHODS;116
11.2;RESULTS;117
11.3;DISCUSSION;121
11.4;SUMMARY;122
11.5;REFERENCES;122
12;CHAPTER 7. EFFECTS OF AN AMINOPEPTIDASE INHIBITOR (BESTATIN) ON HUMAN LYMPHOCYTES I. EFFECT ON POKEWEED MITOGEN-INDUCED IN VITRO IMMUNOGLOBULIN PRODUCTION;124
12.1;MATERIALS AND METHODS;124
12.2;RESULTS;126
12.3;DISCUSSION;132
12.4;SUMMARY;133
12.5;REFERENCES;133
13;CHAPTER 8. EFFECT OF BESTATIN ON BONE MARROW;134
13.1;MATERIALS AND METHODS;134
13.2;RESULTS;135
13.3;DISCUSSION;137
13.4;SUMMARY;138
13.5;REFERENCES;138
14;CHAPTER 9. PRELIMINARY PHASE I STUDY OF BESTATIN IN LUNG CANCER CASES;140
14.1;CLINICAL FINDINGS;140
14.2;CHANGES IN IMMUNOLOGICAL PARAMETERS;141
14.3;SUMMARY;145
14.4;REFERENCES;146
15;CHAPTER 10. PHASE I STUDY OF BESTATIN: (I) A CLINICAL STUDY FOR DETERMINATION OF THE OPTIMAL DOSE OF BESTATIN;148
15.1;METHODS;148
15.2;RESULTS;149
15.3;DISCUSSION;155
15.4;SUMMARY;155
15.5;REFERENCES;156
16;CHAPTER 11. PHASE I STUDY OF BESTATIN: (II) CLINICAL TRIAL OF BESTATIN IN MALIGNANT SKIN TUMORS;158
16.1;MATERIALS;158
16.2;DOSAGE SCHEDULE;158
16.3;RESULTS;160
16.4;DISCUSSION;166
16.5;SUMMARY;167
16.6;REFERENCES;168
17;CHAPTER 12. PHASE I AND PRELIMINARY PHASE II CLINICAL TRIALS OF BESTATIN;174
17.1;MATERIALS AND METHODS;174
17.2;RESULTS;178
17.3;DISCUSSION;185
17.4;SUMMARY;186
17.5;ADDENDUM;186
18;CHAPTER 13. CLINICAL EXPERIENCES IN THE USE OF BESTATIN IN THE TREATMENT OF LOCALLY ADVANCED CANCERS: CASE REPORT;188
18.1;SUMMARY;192
18.2;REFERENCES;192
19;CHAPTER 14. CLINICAL EXPERIENCE WITH BESTATIN IN HEAD AND NECK CANCER;194
19.1;THE MODE OF ADMINISTRATION, CASES AND THE RESULTS;194
19.2;SUMMARY;200
19.3;REFERENCES;200
20;CHAPTER 15. CLINICAL AND EXPERIMENTAL STUDY OF BESTATIN FOR ESOPHAGEAL CANCER;202
20.1;CLINICAL INVESTIGATION;203
20.2;ANIMAL EXPERIMENT;206
20.3;DISCUSSION;208
20.4;SUMMARY;210
20.5;REFERENCES;210
21;CHAPTER 16. CLINICAL EFFECT OF BESTATIN ON MALIGNANT TUMORS OF FEMALE GENITAL ORGANS;216
21.1;METHODS;216
21.2;RESULTS;218
21.3;CONCLUSION;220
21.4;SUMMARY;220
21.5;EXPLANATION OF PHOTOS;221
22;CHAPTER 17. PHARMACOKINETICS AND METABOLISM OF BESTATIN IN HUMANS AND RATS BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY;232
22.1;MATERIALS AND METHODS;232
22.2;RESULTS AND DISCUSSION;234
22.3;SUMMARY;243
22.4;REFERENCES;244
23;APPENDIX: METHODS OF TESTING HUMAN IMMUNE RESPONSES;246
23.1;ONTOGENY OF THE LYMPHATIC SYSTEM;247
23.2;DETERMINATION OF THE CELLULAR COMPOSITION OF [LYMPHOCYTE POPULATIONS;249
23.3;DETERMINATIONS OF THE PROLIFERATIVE RESPONSES OF LYMPHOCYTES TO SPECIFIC AND NONSPECIFIC MITOGENIC STIMULI IN VITRO;252
23.4;STUDIES ON THE FUNCTIONAL ACTIVITY OF B-LYMPHOCYTES;256
23.5;MIGRATION INHIBITION ASSAY FOR THE DETECTION OF SPECIFICALLY-SENSITIZED LYMPHOCYTES;257
23.6;CYTOTOXIC FUNCTIONS OF LYMPHOCYTES;257
23.7;DETECTION OF ANTITUMOR IMMUNITY;259
23.8;SUMMARY;260
23.9;REFERENCES;260